AlphaCentric Life Sciences and Healthcare FundLYFCX
Type
Mutual fund
Peer group
Global equity
Net assets
$39.3M
Expense ratio
2.46%
1-year return
+22.8%
3 years, a year
+7.4%
5 years, a year
+4.1%
Holdings
63
What it aims to do.
The Fund?s investment objective is long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| First American Funds Inc. | 7.72% |
| GILD Gilead Sciences Inc. | 7.18% |
| AZN AstraZeneca PLC | 5.63% |
| VRTX Vertex Pharmaceuticals Incorporated | 5.60% |
| IONS Ionis Pharmaceuticals, Inc. | 3.74% |
| INSM Insmed Inc | 3.57% |
| INCY Incyte Corporation. | 3.41% |
| ROIV Roivant Sciences Ltd | 3.36% |
| ARGX Argenx SE | 3.33% |
| NBIX Neurocrine Biosciences Inc | 3.22% |
More on LYFCX.
- LYFCX overview
- LYFCX holdings
- LYFCX risk
- LYFCX costs
- LYFCX money in and out
- LYFCX share classes
- Compare LYFCX with other funds
Returns after fees, from the fund's SEC filings up to Mar 2026. Past returns are not a promise. Not financial advice.